Eric X. Chen

9.6k total citations · 1 hit paper
162 papers, 5.7k citations indexed

About

Eric X. Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Eric X. Chen has authored 162 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 67 papers in Pulmonary and Respiratory Medicine and 38 papers in Surgery. Recurrent topics in Eric X. Chen's work include Colorectal Cancer Treatments and Studies (35 papers), Lung Cancer Treatments and Mutations (25 papers) and Cancer Genomics and Diagnostics (18 papers). Eric X. Chen is often cited by papers focused on Colorectal Cancer Treatments and Studies (35 papers), Lung Cancer Treatments and Mutations (25 papers) and Cancer Genomics and Diagnostics (18 papers). Eric X. Chen collaborates with scholars based in Canada, United States and Australia. Eric X. Chen's co-authors include Lillian L. Siu, Gregory R. Pond, Amit M. Oza, Sébastien J. Hotte, Patricia A. Tang, Malcolm J. Moore, Benoît You, Eric Winquist, Jennifer J. Knox and Hui Gan and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Eric X. Chen

155 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis

2013 438 citations Lillian L. Siu, Jolie Ringash et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric X. Chen Canada	42	2.5k	1.8k	1.6k	1.6k	878	162	5.7k
Stephen K. Williamson United States	32	4.0k 1.6×	1.2k 0.6×	1.9k 1.2×	1.3k 0.8×	802 0.9×	147	6.0k
Junming Zhu China	11	4.1k 1.6×	1.8k 1.0×	4.3k 2.6×	941 0.6×	879 1.0×	29	7.3k
Lori J. Wirth United States	48	4.3k 1.7×	2.0k 1.1×	2.4k 1.4×	1.8k 1.1×	961 1.1×	260	9.9k
Scott A. Laurie Canada	36	4.3k 1.7×	1.2k 0.7×	3.3k 2.0×	1.2k 0.8×	685 0.8×	163	6.3k
Luis E. Raez United States	37	2.2k 0.9×	1.8k 1.0×	1.7k 1.1×	573 0.4×	1.2k 1.3×	224	4.6k
Kouros Owzar United States	31	1.4k 0.6×	1.3k 0.7×	2.2k 1.4×	1.5k 0.9×	558 0.6×	150	5.9k
Ashley E. Winkler United States	10	3.9k 1.5×	1.1k 0.6×	2.5k 1.5×	1.4k 0.9×	848 1.0×	12	7.3k
Andrew Kramar France	41	1.9k 0.8×	1.1k 0.6×	1.1k 0.6×	1.1k 0.7×	809 0.9×	102	4.6k
George Pentheroudakis Greece	43	4.5k 1.8×	1.6k 0.8×	1.5k 0.9×	983 0.6×	1.3k 1.5×	228	7.6k
Jan B. Vermorken Belgium	23	3.1k 1.2×	1.3k 0.7×	2.1k 1.3×	1.4k 0.9×	499 0.6×	45	5.6k

Countries citing papers authored by Eric X. Chen

Since Specialization

Citations

This map shows the geographic impact of Eric X. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric X. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric X. Chen more than expected).

Fields of papers citing papers by Eric X. Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric X. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric X. Chen. The network helps show where Eric X. Chen may publish in the future.

Co-authorship network of co-authors of Eric X. Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Eric X. Chen. A scholar is included among the top collaborators of Eric X. Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric X. Chen. Eric X. Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nassiri, Farshad, Vikas Patil, Yasin Mamatjan, et al.. (2024). Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype. Acta Neuropathologica. 147(1). 68–68.

Titmuss, Emma, Robert J. Vanner, David F. Schaeffer, et al.. (2024). Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors. Cancer Research Communications. 5(1). 66–73. 2 indexed citations

Loree, Jonathan M., Emma Titmuss, James T. Topham, et al.. (2024). Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial. Clinical Cancer Research. 30(15). 3189–3199. 11 indexed citations

Kim, Richard D., Mustapha Tehfé, Petr Kavan, et al.. (2024). Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clinical Colorectal Cancer. 23(2). 118–127.e6. 8 indexed citations

Rajendran, Luckshi, Zhihao Li, Woo Jin Choi, et al.. (2024). Comparative Outcome Analysis of Lenvatinib Versus Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Transplantation. 109(4). 681–690. 4 indexed citations

Segal, Neil H., Jeanne Tie, Scott Kopetz, et al.. (2024). COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. British Journal of Cancer. 131(6). 1005–1013. 3 indexed citations

Baskurt, Zeynep, Carly C. Barron, Xin Wang, et al.. (2024). Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes. Journal of Neuro-Oncology. 167(1). 111–122. 5 indexed citations

Jiang, Di, Hao‐Wen Sim, Lillian L. Siu, et al.. (2023). Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. Clinical Colorectal Cancer. 22(4). 457–463.

Som, Avik, Jan‐Georg Rosenboom, Eric X. Chen, et al.. (2023). Percutaneous Intratumoral Immunoadjuvant Gel Increases the Abscopal Effect of Cryoablation for Checkpoint Inhibitor Resistant Cancer. Advanced Healthcare Materials. 13(6). e2301848–e2301848. 9 indexed citations

10.

O’Kane, Grainne M., Warren Mason, Pavlina Spiliopoulou, et al.. (2023). Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma. Molecular Cancer Therapeutics. 23(3). 394–399. 6 indexed citations

11.

Amir, Eitan, et al.. (2022). Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies. The Oncologist. 27(6). 487–492.

12.

Doherty, Mark, Vincent C. Tam, Mairéad G. McNamara, et al.. (2022). Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. British Journal of Cancer. 127(8). 1473–1478. 7 indexed citations

13.

Sim, Hao‐Wen, Romina Nejad, Wenjiang Zhang, et al.. (2019). Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas. Clinical Cancer Research. 25(11). 3366–3373. 21 indexed citations

14.

Shepshelovich, Daniel, Amanda Townsend, Osvaldo Espin‐Garcia, et al.. (2018). Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Medicine. 7(11). 5478–5487. 20 indexed citations

15.

Kuczynski, Elizabeth A., Christina R. Lee, Shan Man, Eric X. Chen, & Robert S. Kerbel. (2015). Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. Cancer Research. 75(12). 2510–2519. 72 indexed citations

16.

Péron, Julien, Denis Maillet, Hui Gan, Eric X. Chen, & Benoît You. (2013). Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review. Journal of Clinical Oncology. 31(31). 3957–3963. 90 indexed citations

17.

Xu, Junyao, Jennifer J. Knox, Emin Ibrahimov, et al.. (2012). Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer. Clinical Cancer Research. 19(1). 118–127. 24 indexed citations

18.

Infante, Jeffrey R., D. Ross Camidge, Linda Mileshkin, et al.. (2012). Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors. Journal of Clinical Oncology. 30(13). 1527–1533. 195 indexed citations

19.

Stathis, Anastasios, Sébastien J. Hotte, Eric X. Chen, et al.. (2011). Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas. Clinical Cancer Research. 17(6). 1582–1590. 79 indexed citations

20.

Knox, Jennifer J., Rebecca Wong, A. Visbal, et al.. (2010). Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer. 116(17). 4023–4032. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact